Browse SV2B

Summary
SymbolSV2B
Namesynaptic vesicle glycoprotein 2B
Aliases KIAA0735; HsT19680; synaptic vesicle protein 2B homolog
Chromosomal Location15q26.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane Multi-pass membrane protein Cytoplasmic vesicle, secretory vesicle, acrosome Note=Associated with synaptic-like microvesicles but not with insulin-containing vesicles in insulin-secreting cells of the pancreas (By similarity). Localizes to microvesicles in the pinealocytes. Localizes to the acrosome in spermatids (By similarity).
Domain PF07690 Major Facilitator Superfamily
PF13599 Pentapeptide repeats (9 copies)
PF00083 Sugar (and other) transporter
Function

Probably plays a role in the control of regulated secretion in neural and endocrine cells.

> Gene Ontology
 
Biological Process GO:0001504 neurotransmitter uptake
GO:0001505 regulation of neurotransmitter levels
GO:0006836 neurotransmitter transport
GO:0098657 import into cell
Molecular Function -
Cellular Component GO:0001669 acrosomal vesicle
GO:0008021 synaptic vesicle
GO:0030133 transport vesicle
GO:0030141 secretory granule
GO:0030658 transport vesicle membrane
GO:0030659 cytoplasmic vesicle membrane
GO:0030672 synaptic vesicle membrane
GO:0070382 exocytic vesicle
GO:0097223 sperm part
GO:0098793 presynapse
GO:0099501 exocytic vesicle membrane
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04512 ECM-receptor interaction
Reactome R-HSA-1643685: Disease
R-HSA-5663205: Infectious disease
R-HSA-168799: Neurotoxicity of clostridium toxins
R-HSA-5250968: Toxicity of botulinum toxin type A (BoNT/A)
R-HSA-5250955: Toxicity of botulinum toxin type D (BoNT/D)
R-HSA-5250992: Toxicity of botulinum toxin type E (BoNT/E)
R-HSA-5250981: Toxicity of botulinum toxin type F (BoNT/F)
R-HSA-5339562: Uptake and actions of bacterial toxins
Summary
SymbolSV2B
Namesynaptic vesicle glycoprotein 2B
Aliases KIAA0735; HsT19680; synaptic vesicle protein 2B homolog
Chromosomal Location15q26.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SV2B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSV2B
Namesynaptic vesicle glycoprotein 2B
Aliases KIAA0735; HsT19680; synaptic vesicle protein 2B homolog
Chromosomal Location15q26.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SV2B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.59 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSV2B
Namesynaptic vesicle glycoprotein 2B
Aliases KIAA0735; HsT19680; synaptic vesicle protein 2B homolog
Chromosomal Location15q26.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SV2B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1020.689
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2740.55
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0180.965
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.990.107
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.190.316
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.7390.599
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.340.678
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15112.2880.0554
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.90.15
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1380.735
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.2530.656
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.330.286
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SV2B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.82.712.10.0439
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.83.411.40.0746
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSV2B
Namesynaptic vesicle glycoprotein 2B
Aliases KIAA0735; HsT19680; synaptic vesicle protein 2B homolog
Chromosomal Location15q26.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SV2B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSV2B
Namesynaptic vesicle glycoprotein 2B
Aliases KIAA0735; HsT19680; synaptic vesicle protein 2B homolog
Chromosomal Location15q26.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SV2B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SV2B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSV2B
Namesynaptic vesicle glycoprotein 2B
Aliases KIAA0735; HsT19680; synaptic vesicle protein 2B homolog
Chromosomal Location15q26.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SV2B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSV2B
Namesynaptic vesicle glycoprotein 2B
Aliases KIAA0735; HsT19680; synaptic vesicle protein 2B homolog
Chromosomal Location15q26.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SV2B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSV2B
Namesynaptic vesicle glycoprotein 2B
Aliases KIAA0735; HsT19680; synaptic vesicle protein 2B homolog
Chromosomal Location15q26.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SV2B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSV2B
Namesynaptic vesicle glycoprotein 2B
Aliases KIAA0735; HsT19680; synaptic vesicle protein 2B homolog
Chromosomal Location15q26.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SV2B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.